Searched for
BIOCON FUNDRAISE
Kiran Mazumdar-Shaw's Immuneel Therapeutics raises Rs 100 crore from Singularity AMC, Rainmatter, othersThe Bengaluru-based company makes CAR-T therapy, a form of cancer treatment where a patient’s own immune cells are taken out, trained in a ...- Biocon QIP to ease balance sheet pressure; metals, PSU banks favoured in near term: Nischal MaheshwariBiocon's fundraising is viewed positively to manage debt. Expert Nischal Maheshwari is optimistic about Biocon's future, expecting earlier ...
- Biocon shares in focus ahead of board meeting, fundraising plansBiocon shares: Biocon’s Board will meet on Saturday, December 6, 2025, to decide on key proposals that could shape its growth and sharehold...
- Biocon shares jump 3% to hit new 52-week high on $4.5 billion Biologics IPO, merger reviewBiocon shares hit a new 52-week high after the company confirmed it is evaluating a potential merger of Biocon Biologics with the parent en...
- Biocon considers merging Biocon Biologics in $4.5 billion deal; IPO and share swap options under reviewBiocon is exploring merging its biosimilars arm, Biocon Biologics, with itself, potentially valuing the unit at $4.5 billion. The company i...
- Biocon reports 95% YoY decline in net profit, operating revenue up 15%Biocon's Q1 net profit declined 95% year-on-year, but on a like-for-like basis, profit after tax increased by 65%. Revenue grew 15% to Rs 3...
- Biocon raises Rs 4,500 crore through successful QIPBiocon, a leading biopharmaceutical company, successfully raised Rs 4,500 crore through QIP. This marks their first equity funding since 20...
- Biocon plans ₹4,500-cr QIP to raise stake in Biologics unit: Kiran ShawBiocon is planning a ₹4,500 crore fundraise to increase promoter stake in Biocon Biologics and convert structured venture debt into equity,...
- Biocon shares fall 3% after board approves fundraise of up to Rs 4,500 croreBiocon shares: The board approved a hike in the company’s authorised share capital from Rs 625 crore to Rs 700 crore, along with a correspo...
- Biocon Biologics is planning to raise $950 million through overseas bondsBiocon Biologics plans to raise $950 million through overseas bond sales to refinance a significant portion of its $1.2-billion debt from a...
- Stocks in news: ZEE, M&M Financial, Dr Reddy's, Wipro, BioconDomestic markets rally on exit polls predicting Modi government's massive mandate. ZEE, M&M Financial, Dr Reddy's, Wipro, Biocon in focus. ...
- Looking at additional fundraisers to further reduce acquisition debt: Kiran Mazumdar Shaw, BioconNo, there was no understanding to have operational involvement, but we had offered a board seat and that will remain and it is for Serum to...
- Immuneel Therapeutics raises $15 million in fundingImmuneel Therapeutics is working on developing its own pipeline of chimeric antigen receptor T-cell (CAR-T) therapies and other cellular im...
- Biocon to use debt, equity and IPO to buy Viatris biosimilars biz: Kiran Mazumdar Shaw“It will be a mix of debt, equity and of course IPO. It is going to be a very interesting business opportunity and a very comfortable aspec...
- Market movers: Biocon plunges 11%, Shankara Building jumps 10%When Biocon said it will buy US-based Viatris Inc's biosimilars business in a transaction valued at $3.34 billion that will increase debt o...
- Biocon Biologics to expand to Latin America, Africa and Asia“We are investing thoughtfully to expand the global footprint step by step across the world. We have opened regional offices across Latin A...
- Biocon Biologics eyes $200m, plans IPO in 2 years: Mazumdar-ShawIt looks to build a pipeline of 28 biosimilars across global markets in three phases.
- True North to acquire 2.4% stake in Biocon BiologicsDeal values Biocon Biologics at $3 billion
- True North buys into Biocon Biologics, deal values firm at around $3.5 billionTrue North has acquired about 3 per cent of Biocon Biologics India Ltd (BBIL), a wholly owned subsidiary of Biocon, for $100 million, valui...
- USFDA nod for cancer biosimilar is a big triumph: Kiran Mazumdar ShawAfter initial hiccups with the US and EU drug regulators, Shaw said this approval signifies India and her company’s capability in developin...
Load More
